A Personal View of Genomics

It wasn't easy getting to the 4th International Meeting on Single Nucleotide Polymorphisms and Complex Genome Analysis held Oct. 10-15 at the Wenner-Gren Foundation in Stockholm. A week earlier, as flight cancellations continued in the wake of the Sept. 11 terrorist attacks, SwissAir had declared bankruptcy and an SAS jet had crashed in Milan, further disrupting schedules. So it was little surprise that several speakers had to phone in their talks. But not J. Craig Venter, president and chief sc

Written byRicki Lewis
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

"It is extremely important not to let the individuals who perpetrated these acts control our lives. I'm not controlled by them. We must all act in a normal fashion," he began, and then launched into an account of activities at Celera, past and future. But it was an unexpected musing about the uncertain present that explained his opening comments, and left the audience spellbound.

File Photo

Craig Venter

Venter began by speaking, like a father bragging about his firstborn, about Haemophilus influenzae, the organism that occupies a place in history as the first to have its genome sequenced.1 It is a bittersweet memory, marking one of several stops on Venter's career path where his ideas were dismissed as incredible. First came expressed sequence tag (EST) technology, over which he left the National Institutes of Health to found the not-for-profit The Institute for Genomic Research (TIGR) in Rockville in 1991. In ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies